Skip to content

Rapport Therapeutics

US · RAPP #2970 by market cap Listed 2024
23.16 -0.43 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 23.17 -1.78%
After-hours 23.16 0.00%
52.5022.5023.162026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RAPP?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -32.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 7.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -28.2% Better than 13%
Return on invested capital -31.2% Better than 10%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -52.0% Better than 5%
6-month return -38.6% Better than 13%
12-month return (ex latest month) -4.8% Better than 28%
Distance below 52-week high 56.2% Better than 14%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 26.2x Better than 99%
Debt to assets 2.2% Better than 87%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 193.6% Better than 94%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.43%
1M -21.14%
3M -51.60%
6M -35.16%
YTD -23.67%
1Y -13.74%

Key statistics

Price & volume

Prev close
23.59
Open
23.23
Day range
23.00 - 23.83
Avg price
23.30
Volume
437.72K
Turnover
10.20M
Amplitude
3.52%
52-week range
22.06 - 52.93

Valuation

P/E
-8.10
P/E (TTM)
-7.31
P/B
3.51
EPS
-2.86
Net profit
-169.54M
Net assets
391.19M

Share structure

Market cap
1.37B
Float cap
941.89M
Shares out
59.28M
Float shares
40.67M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-06-07
52-week range 4% of range
22.06 52.93

56.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-4.96M net over the window

Short interest

Shares short
3.96M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Rapport Therapeutics (RAPP)?

Rapport Therapeutics last traded at 23.16. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Rapport Therapeutics's market cap?

About 1.37B.

What is the P/E ratio of Rapport Therapeutics?

The trailing twelve-month P/E is -7.31. The Valuation tab shows it against the stock's own five-year range.

Does Rapport Therapeutics pay a dividend?

Rapport Therapeutics does not currently pay a regular dividend.

Is Rapport Therapeutics a buy according to analysts?

The consensus of 14 analysts is a Buy rating, with an average 12-month price target of 68.00, which implies 193.6% upside from the current price. This is not investment advice.

What is Rapport Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Rapport Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Rapport Therapeutics discussion 0 comments

Add a comment